NASH drug treatment development : challenges and lessons
NASH drug treatment development : challenges and lessons
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood. As cardiovascular disease is the predominant cause of mortality in people with NAFLD, future pharmacotherapies for NAFLD must consider associated cardiometabolic risk factors. The successful use of glucose-lowering drugs in the treatment of type 2 diabetes in patients with NAFLD indicates that this strategy is important, and worth developing further. Greater public awareness of NAFLD is needed because collaboration between all stakeholders is vital to enable a holistic approach to successful treatment.
943-954
Tilg, Herbert
fac1edba-7a3e-4bd4-8fd5-845ef9a982aa
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
26d18b17-b89e-4a95-9ec6-5b2bda8fbe75
1 October 2023
Tilg, Herbert
fac1edba-7a3e-4bd4-8fd5-845ef9a982aa
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
26d18b17-b89e-4a95-9ec6-5b2bda8fbe75
Tilg, Herbert, Byrne, Christopher D. and Targher, Giovanni
(2023)
NASH drug treatment development : challenges and lessons.
The Lancet Gastroenterology & Hepatology, 8 (10), .
(doi:10.1016/S2468-1253(23)00159-0).
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood. As cardiovascular disease is the predominant cause of mortality in people with NAFLD, future pharmacotherapies for NAFLD must consider associated cardiometabolic risk factors. The successful use of glucose-lowering drugs in the treatment of type 2 diabetes in patients with NAFLD indicates that this strategy is important, and worth developing further. Greater public awareness of NAFLD is needed because collaboration between all stakeholders is vital to enable a holistic approach to successful treatment.
Text
NASH treatment development_Lancet GH_clean_19052023
- Accepted Manuscript
Restricted to Repository staff only until 19 May 2024.
Request a copy
Text
Figure 1_new
- Accepted Manuscript
Restricted to Repository staff only until 19 May 2024.
Request a copy
Text
Figure 2_new
- Accepted Manuscript
Restricted to Repository staff only until 19 May 2024.
Request a copy
Text
Figure 3_new
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 19 May 2023
e-pub ahead of print date: 16 August 2023
Published date: 1 October 2023
Additional Information:
Funding information:
HT is supported by the excellence initiative VASCage (Centre for Promoting Vascular Health in the Ageing Community), an R&D K-Centre (COMET program - Competence Centers for Excellent Technologies) funded by the Austrian Ministry for Transport, Innovation and Technology, the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg and Vienna. CDB is supported in part by the Southampton National Institute for Health and Care 19 Research UK, Biomedical Research Centre NIHR grant code, NIHR203319. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy.
Identifiers
Local EPrints ID: 477628
URI: http://eprints.soton.ac.uk/id/eprint/477628
ISSN: 2468-1253
PURE UUID: f83e7a0a-2033-4c76-a1ba-f18a704d5d60
Catalogue record
Date deposited: 09 Jun 2023 16:56
Last modified: 17 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
Herbert Tilg
Author:
Giovanni Targher
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
